Two drug discovery initiatives for UniQuest
11 November, 2015The commercialisation company of The University of Queensland, UniQuest, will be part of two separate drug discovery initiatives.
Invion's share purchase plan and asthma trial
10 November, 2015Invion has opened a share purchase plan (SPP), allowing eligible shareholders to purchase up to $15,000 worth of shares at a discount and without any brokerage or transaction costs.
A heart failure drug that reduces scar tissue
09 November, 2015Drug development company Armaron Bio has begun its Phase II clinical trial for NP202, its lead candidate drug for heart failure.
The importance of transparency
03 November, 2015 by Dr Andrew Weekes, Medical Director, GSK AustraliaStudying experimental medicines in people is a vital part of the development process for all new medicines and vaccines. GSK Australia Medical Director Dr Andrew Weekes recognises the importance of publicly disclosing this research.
Potential new treatment for tuberculosis
29 October, 2015Scientists have discovered a potential new treatment for tuberculosis — a disease whose resistance to current medical therapies has enabled it to infect 30% of the globe's population.
Tennis elbow tendon treatment results
28 October, 2015Orthocell has released positive follow-up data from a study of its tendon cell treatment for tennis elbow in workers compensation patients.
Licence agreement for TGR immunoassay technology
26 October, 2015TGR BioSciences has announced a European licence agreement with Prime Diagnostics — a developer of high-quality diagnostics, technologies and services for the agricultural sector.
Nanodelivery trials get the go-ahead
22 October, 2015Medlab Clinical has been granted ethics approval to begin two separate human trials using its nanotechnology delivery platform, NanoCelle. The platform, previously developed for cannabis research, converts pharmaceuticals into nanoparticle form.
Cynata collaborates on cell therapy for cancer
14 October, 2015Cynata Therapeutics will collaborate with Massachusetts General Hospital on the development of modified mesenchymal stem cells (MSCs) to treat cancer.
Phosphagenics restructure effective immediately
13 October, 2015Drug delivery company Phosphagenics has announced a corporate restructure, effective immediately, following its recent strategic review.
ResMed completes Curative Medical acquisition
12 October, 2015ResMed has completed its acquisition of Curative Medical, a provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories to the Chinese market.
Paranta Biosciences commences cystic fibrosis trial
06 October, 2015Paranta Biosciences has successfully closed a $7 million financing round, which it will use to fund the development of treatments for inflammatory and fibrotic lung diseases.
A new drug analysis method
02 October, 2015An international team of scientists has been working with a major biopharmaceutical company to investigate new ways to characterise protein formulations.
US$53.9m for Avita to support mass burn injuries
30 September, 2015Avita Medical has been awarded a contract with BARDA, worth up to $53.9 million, which supports late-stage clinical development and procurement of Avita's ReCell autologous cell harvesting device under a mass casualty preparedness program.
The Daraprim price hike and the TPP
28 September, 2015 by Lauren DavisAfter a tumultuous week for Turing Pharmaceuticals — which saw the company raise the price of an essential medicine by over 4000%, only to lower it again in the face of universal criticism — an Australian intellectual property expert warns that similar incidents could occur as a result of the Trans-Pacific Partnership (TPP).
